Melanoma vaccines: A review

Giornale Italiano di Dermatologia e Venereologia

Volumn 141, Issue 1, 2006, Pages 33-43

  Elias, E G ^a  

^a Weinberg Cancer Institute   (United States)

Author keywords

Melanoma; Skin; Vaccines

Indexed keywords

2,4 DINITROPHENOL; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; BCG VACCINE; CANCERVAX; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; DNA VACCINE; GANGLIOSIDE GM2; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN; INTERLEUKIN 12; INTERLEUKIN 2; KEYHOLE LIMPET HEMOCYANIN; MELACINE; MELAN A; MELANOMA ANTIGEN; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 3; MELANOMA VACCINE; MITOMYCIN C; PEPTIDE DERIVATIVE; QS 21; TUBERCULIN; VACCINIA ONCOLYSATE; VIRUS VACCINE;

ANTIGEN SPECIFICITY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CELL LYSATE; CHILL; CLINICAL TRIAL; DELAYED HYPERSENSITIVITY; DISEASE COURSE; FEVER; HEADACHE; HIGH RISK PATIENT; HUMAN; IMMUNE SYSTEM; IMMUNOSTIMULATION; INJECTION SITE ERYTHEMA; MELANOMA; METASTASIS; MICROMETASTASIS; REVIEW; SYSTEMIC DISEASE; SYSTEMIC THERAPY; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT;

EID: 33645112640     PISSN: 03920488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Balch CM, Houghton AN, Sober AJ, Soong, SL. Cutaneous Melanoma. 4th ed. St. Louis, MO: Quality Medical Publishing; 2003.
2. Koh HK, Sober AJ, Nakagawa H, Albert DM, Mihm MC, Fitzpatrick TB. Malignant melanoma and vitiligo-like leukoderma. An electron microscopic study. J Am Acad Dermatol 1983;9:696-708.
3. Bystryn, JC, Riegel D, Friedman RJ, Kopf A. Prognostic significance of hypopigmentation in malignant melanoma. Arch Dermatol 1987;123:1053-5.
4. Duhra P, Ilchyshyn A. Prolonged survival in metastatic malignant melanoma associated with vitiligo. Clin Exp Dermatol 1991;16: 303-5.
5. Morton DL, Eilber FR, Homes EC, Hunt JS, Ketchum AS, Silverstein MJ et al. BCG immunotherapy of malignant melanoma. Summary of seven years experience. Ann Surg 1974;180:635-43.
6. Yao TJ, Meyers M, Livington PO, Houton AN, Chapman BP. Immunization of melanoma patients with BEC2-keyhole limpet hemocyanin plus BCG intradermally followed by intravenous booster immunization with BEC2 to induce anti-CD3 ganglioside antibodies. Clin Cancer Res 1999;5:77-81.
7. Wolchok JD, Weber JS, Houton AN, Livington PO. Melanoma vaccines. In: Balch CM, Houghton AN, Sober AJ, Soong SL editors. Cutaneous melanoma. St. Louis, MO: Quality Medical Publishing, Inc.; 2003. p. 645-56.
8. Brocker EB, Zwadlo G, Suter L, Brune M, Sorg C. Infiltration of primary and metastatic melanoma with macrophages of the 25F9-positive phenotype. Cancer Immunol Immunother 1978;25:81-6.
9. Torisu H, Ono M, Kiryu H, Furue M, Ohmoto Y, Nakayam S et al. Macrophages infiltration correlates with tumor stage and angiogenesis in human malignant melanoma. Possible involvement of INF alpha and IL-1 alpha. Int J Cancer 2000;85:182-7.
10. Sumner WC, Foraker AG. Spontaneous regression of human melanoma: clinical and experimental studies. Cancer 1960;13:79-81.
11. Elias EG. Is there an established role for immunotherapy for any of our surgical cancer? J Surg Oncol 1991;48:149-52.
12. Barth A, Morton DL. The role of adjuvant therapy in melanoma management. Cancer 1995;75:726-34.
13. Storm FK, Sparks FC, Morton DL. Treatment of melanoma of the lower extremity with intralesional injection of bacillus Calmette-Guerin and hyperthermic perfusion. Surg Gynecol Obstet 1979;149: 17-21.
14. Cascinelli N, Rumke P, Mackie R, Morabita A, Bufalino R. The significance of conversion of skin reactivity to efficacy of bacillus Calmette-Guerin (BCG) vaccination given immediately after radical surgery in stage II melanoma patients. Cancer Immunol Immunother 1989;28:282-6.
15. Czarnetzki BM, Macher E, Suciu S, Thomas D, Steerenberg PA, Rumke P. Long-term adjuvant immunotherapy in stage I high risk malignant melanoma, comparing two BCG preparations versus non-treatment in randomized multicenter study (EORTC Protocol 18781). Eur J Cancer 1993;29A:1237-42.
16. Lipton A, Harvey HA, Lawrence B, Gottlieb R, Kukrika M, Dixon R et al. Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma. Cancer 1983;51:57-60.
17. Lipton A, Harvey HA, Balch CM, Autle CE, Heckard R, Bartolucci AA. Corynebacterium parvum versus bacille Calmette-Guerin adjuvant immunotherapy of stage II malignant melanoma. J Clin Oncol 1991;9:1151-6.
18. Elias EG, Tomazic VJ, Buda BS. Adjuvant immunotherapy in melanoma: a new approach. J Surg Oncol 1992;50:144-8.
19. Barth A, Hoon DS, Foshag LJ, Nizze JA, Famatiga E, Okun E et al. Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response. Cancer Res 1994;54: 3342-5.
20. Morton DL, Foshag LJ, Hoon DS, Nizze JA, Famatiga E, Wanek LA et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1992;216:463-82.
21. Morton DL, Barth A. Vaccine therapy for malignant melanoma. CA Cancer J Clin 1996;26:225-44.
22. Elias EG, Suter CM, Fabian DS. Adjuvant immunotherapy in melanoma with irradiated autologous tumor cells and low dose cyclophosphamide. J Surg Oncol 1997;64:17-22.
23. Berd D, McGuire HC, Schuchter LM, Hamilton R, Hauck WW, Sato T et al. Autologous hapten-modified melanoma vaccine as post-surgical adjuvant treatment after resection of nodal metastases. J Clin Oncol 1997;15:2359-70.
24. Berd D, Sato T, McGuire HC, Kairys J, Mastrangelo MJ. Immunopharmacologic analysis of an autologous hapten-modified human melanoma vaccine. J Clin Oncol 2004;22:403-15.
25. Sosman JA, Weeraratna AT, Sondak VK. When will melanoma vaccines be proven effective? J Clin Oncol 2004;22:387-9.
26. Ramarathinam L, Sarma S, Marie M, Zhao M, Yang G, Chen L et al. Multiple lineages of tumors expressed a common tumor antigens, P1A, but they are not cross protected. J Immunol 1995;155:5323-9.
27. Wallack MK, Sivanandham M, Balch CM, Urist MM, Bland KI, Murray D et al. A phase III randomized, double-blind, multi-institutional trial of vaccinia melanoma Oncolysate-active specific immunotherapy for patients with stage II melanoma. Cancer 1995;75:34-42.
28. Wallack MK, Sivananham M, Balch CM, Urist MM, Bland KI, Murray D et al. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: The final analysis of data from a phase III, randomized, double-blind, multi-center vaccinia melanoma oncolysates trial. J Am Coll Surg 1998;187:69-77.
29. Hersey P, Edwards A, Coates A, Shaw H, McArthy W, Milton G. Evidence that treatment with vaccinia melanoma cell lysates (VMCL) may improve survival of patients with stage II melanoma. Cancer Immunol Immunother 1987;25:257-65.
30. Hersey P, Coates AS, McArthy WH, Thompson JF, Sillar RW, McLeod R et al. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of randomized trial. J Clin Oncol 2002;20:4181-90.
31. Sosman JA, Unger JM, Liu PY, Flaherty LE, Park MS, Kempf RA et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with allogenic tumor vaccine. Impact of HLA class I antigen expression on outcome. J Clin Oncol 2002;20:2067-75.
32. Portoukalian J, Zwingelstein G, Dore J. Lipid composition of human malignant melanoma tumors at various levels of malignant growth. Eur J Biochem 1979;94:19-23.
33. Tsuchida T, Saxton RG, Morton DL, Irie RT. Gangliosides of human melanoma. J Natl Cancer Inst 1987;78:45-54.
34. Livingston PO, Wong GYC, Adluri S, Tuo Y, Pada M, Parente R et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994;12:1036-44.
35. Helling F, Zhang S, Shang A, Adluri S, Calves M, Koganty R et al. GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res 1995;55:2783-8.
36. Ragupathi G, Livington PO, Hood C, Gathuru J, Krown SE, Chapman PB et al. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Clin Cancer Res 2003;9:5214-20.
37. Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MC et al. High-dose Interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of inter-group trial E1694/ S9512/ C509801. J Clin Oncol 2001;19:2370-80.
38. Ribas A, Butterfield LH, Glaspy JA, Economou JS. Current development in cancer vaccines and cellular immunotherapy. J Clin Oncol 2003;21:2415-32.
39. Castelli C, Revoltini L, Andreola G, Carraba M, Renkvist N, Parmiani G. T-cell recognition of melanoma-associated antigens. J Cell Physiol 2000;182:323-31.
40. Wang F, Bade E, Kuniyoshi C, Spears L, Jeffery G, Marty V et al. Phase I trial of MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin Cancer Res 1999;5:2756-65.
41. Smith JW, Walker EB, Fox BA, Haley D, Wisner KP, Doran T et al. Adjuvant immunization of HLA-A2-positive melanoma patients with modified gp100 peptide induces peptide-specific CD8+ T-cell responses. J Clin Oncol 2003;21:1562-73.
42. Rosenberg SA, Sherry RM, Morton KE, Scharfman WJ, Yang JC, Topalian SL et al. Tumor progression can occur despite the induction of very high levels of self tumor antigen-specific CD8+ T-cells in patients with melanoma. J Immunol 2005;175:6169-76.
43. Hu X, Chakraborty NG, Sporn JR, Kurtzman SH, Ergin MT, Mukherji B. Enhancement of cytotoxic T lymphocyte precursor frequently in melanoma patients following immunization with MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res 1996;56:2479-83.
44. Kruit WJ, van Ojik HH, Brichard VG, Escudier B, Dorval T, Dreno B et al. Phase 1 and II study of subcutaneous and intradermal immunization with recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Inter J Cancer 2005;117:596-604.
45. Pullarkat V, Lee PP, Scotland R, Rubio V, Groshen S, Gee C et al. A phase I trial of SD-9427 (progenipoietin) with multipeptide vaccine for resected metastatic melanoma. Clin Cancer Res 2003;9:1301-12.
46. Belli F, Testori A, Revoltini L, Maio M, Andreola G, Sertoli M et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complex: clinical and immunologic findings. J Clin Oncol 2002;20:4169-80.
47. deVries IJ Bernsen MR, Lesterhuis WJ, Scharenborg NM, Strijk SP, Gerritsen MJP et al. Immunomonitoring specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol 2005;23:5779-87.
48. Bedrosian I, Mick R, Xu S, Nisenbaum H, Faries M, Zhang P et al. Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients. J Clin Oncol 2003;21:3826-35.
49. Smith SG, Patel PM, Porte J, Selby PJ, Jackson AM. Human dendritic cells genetically engineered to express a melanoma polypeptide DNA vaccine induce multiple cytotoxic T-cell responses. Clin Cancer Res 2001;7:4253-61.
50. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalin SL et al. Immunologic and therapeutic evaluation of synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4:321-7.
51. Rosenberg SA, Zhai Y, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM et al. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst 1998;90:1894-900.
52. Toda M, Martuza RL, Kojima H, Rabkin SD. In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity. J Immunol 1998;160:4457-64.
53. Bystryn JC, Henn M, Li J, Shroba S. Identification of immunogenic human melanoma antigens in a polyvalent melanoma vaccine. Cancer Res 1992;52:5948-53.
54. Bystryn JC, Jacquotte AZ, Oratz R, Shapiro RL, Harris MN, Roses DF. Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine. Clin Cancer Res 2001;7:1882-7.
55. Reynolds SR, Jacquotte AZ, Shapiro RL, Roses DF, Harris MN, Johnson D et al. Vaccine-induced CD8+ T-cell responses to MAGE-3 correlate with clinical outcome in patients with melanoma. Clin Cancer Res 2003;9:657-62.
56. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST1684. J Clin Oncol 1996;14:7-17.
57. Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA 1994;271:907-13.
58. Spitler LE, Grossbard ML, Ernstoff MS, Silver G, Jacobs M, Hayes FA et al. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony stimulating factor. J Clin Oncol 2000;18:1614-21.
59. Lee P, Wang F, Kuniyoshi J, Rubio V, Stuges T, Groshen S et al. Effects of interleukin-12 on the immune response to multipeptide vaccine for resected metastatic melanoma. J Clin Oncol 2001;19: 3836-47.
60. Luiten RM, Kueter EWM, Mooi W, Galle PW, Rankin EM, Gerritsen WR et al. Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma. J Clin Oncolol 2005;23:8978-91.